Tag: KZA
Kazia Therapeutics reports good half-year progress despite market challenges
Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) has made good progress in the first six months of the year with pipeline assets paxalisib and EVT801 despite a challenging equity market f...
Kazia Therapeutics collars US FDA orphan drug designation for paxalisib in a highly aggressive childhood brain cancer
Kazia Therapeutics (ASX: KZA) has collared orphan drug designation (ODD) from the United States Food and Drug Administration for its lead candidate paxalisib in treating a rare and highly aggressive c...
Kazia Therapeutics presents ‘positive data’ on paxalisib in childhood brain cancers
“Positive data” is being presented regarding the activity of Kazia Therapeutics’ (ASX: KZA) lead drug paxalisib in two forms of childhood brain cancers.
The company is presenting the data via two p...
Kazia Therapeutics expands paxalisib study to include secondary brain tumours from breast cancer
Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) is expanding a phase two study of its drug paxalisib in patients with brain metastases to include those starting from breast cancer.
Th...
Kazia Therapeutics adds recruitment sites to paxalisib arm of global glioblastoma study
Oncology-focused drug development company Kazia Therapeutics (ASX: KZA) has confirmed the multi-drug platform study GBM AGILE has opened recruitment to its paxalisib arm in Europe.
GBM AGILE is a g...
Kazia Therapeutics establishes ‘at-the-market’ equity program
Oncology-focused biotechnology company Kazia Therapeutics (ASX: KZA) has established an ‘at-the-market’ (ATM) equity program, appointing US-based investment bank Oppenheimer & Co Inc as the sales ...
Kazia Therapeutics completes phase II trial of paxalisib in glioblastoma
Kazia Therapeutics (ASX: KZA) is preparing to present the results of a phase II study evaluating its lead drug paxalisib in glioblastoma, which is the most aggressive form of brain cancer.
The phas...
Kazia Therapeutics’ paxalisib shows activity against rare childhood brain cancer in pre-clinical research
Kazia Therapeutics (ASX: KZA) has revealed pre-clinical data that its drug paxalisib demonstrates activity in two forms of childhood brain cancer where there is a very high unmet medical need.
The ...
Kazia Therapeutics recruits first keto patient to phase II paxalisib study for treatment of glioblastoma
Oncology-focused drug development company Kazia Therapeutics (ASX: KZA) has recruited its first patient into a phase II study of investigational new drug paxalisib for the treatment of newly-diagnosed...
Kazia Therapeutics advances human trials for lead cancer drugs during December quarter
Oncology-focused and clinical stage biotechnology company Kazia Therapeutics (ASX: KZA) has reported strong progress on the development of its lead drug candidates during the three months to 31 Decemb...
Kazia Therapeutics’ paxalisib drug granted fast track designation for treatment of glioblastoma
Australian oncology-focused biotechnology company Kazia Therapeutics (ASX: KZA) has been granted Fast Track Designation by the US Food & Drug Administration for its lead drug paxalisib (formerly G...
FDA grants Kazia Therapeutics’ paxalisib drug rare paediatric disease designation
Kazia Therapeutics (ASX: KZA) has been awarded Rare Pediatric Disease Designation (RPDD) for its lead drug paxalisib by the FDA for treating Diffuse Intrinsic Pontine Glioma (DIPG).
RPDD status mea...
Kazia Therapeutics’ lead brain cancer drug selected for international study
Kazia Therapeutics’ (ASX: KZA) lead drug GDC-0084 has been selected for use in GBM AGILE, which is an international academic-led glioblastoma study.
According to Kazia, GBM AGILE is an adaptive pha...
Kazia Therapeutics reports positive early results from phase 2 glioblastoma trial using GDC-0084
Biotechnology company Kazia Therapeutics (ASX: KZA) has reported early data from a phase 2 study into the effects of lead candidate GDC-0084 on newly-diagnosed brain glioblastomas in adults has shown ...
Kazia Therapeutics unveils fresh clinical trial for its brain cancer drug candidate
Biotechnology company Kazia Therapeutics (ASX: KZA) has taken a definitive step towards proving the safety and efficacy of its investigational new drug GDC-0084, after announcing a “state of the art” ...
Kazia Therapeutics commences clinical trial to redress the balance in glioblastoma treatment options
Glioblastoma is one of the most debilitating and deadly cancers, with limited treatment options that are currently effective for only a third of patients, says Kazia Therapeutics (ASX: KZA) CEO Dr Jam...
